Sequential delivery of LAIV and SARS-CoV-2 in the ferret model can reduce SARS-CoV-2 shedding and does not result in enhanced lung pathology
| Autor: | Kathryn A. Ryan, Jonathan Crowe, Katarzyna E Schewe, Robert J. Watson, Richard Humphreys, Catherine J. Whittaker, Jemma Paterson, Miles W. Carroll, Francisco J. Salguero, Yper Hall, Oliver Dibben, Emma Rayner, Anthony C. Marriott, Susan A. Fotheringham |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Influenza vaccine
business.industry viruses Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) fungi virus diseases Disease Lung pathology body regions Regimen medicine.anatomical_structure Immunology Pandemic Medicine Live attenuated influenza vaccine skin and connective tissue diseases business Respiratory tract |
| DOI: | 10.1101/2021.02.01.429110 |
| Popis: | Co-circulation of SARS-CoV-2 and influenza viruses could pose unpredictable risks to health systems globally, with recent studies suggesting more severe disease outcomes in co-infected patients. The lack of a readily available COVID-19 vaccine has reinforced the importance of influenza vaccine programmes during the COVID-19 pandemic. Live Attenuated Influenza Vaccine (LAIV) is an important tool in protecting against influenza, particularly in children. However, it is unknown whether LAIV administration might influence the outcomes of acute SARS-CoV-2 infection or disease. To investigate this, quadrivalent LAIV (QLAIV) was administered to ferrets 3 days pre- or post-SARS-CoV-2 infection. LAIV administration did not exacerbate SARS-CoV-2 disease course or lung pathology with either regimen. Additionally, LAIV administered prior to SARS-CoV-2 infection significantly reduced SARS-CoV-2 replication and shedding in the upper respiratory tract (URT). We conclude that LAIV administration in close proximity to SARS-CoV-2 infection does not exacerbate mild disease and can reduce SARS-CoV-2 shedding. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|